Navigation Links
European patient registry in venous thromboembolism (VTE) - PREFER in VTE - enrols first patient
Date:2/6/2013

MUNICH, February 6, 2013 /PRNewswire/ --

The registry plans to gather data from more than 4,000 patients with VTE across seven European countries, providing insights into the clinical management of a disease that is a leading cause of morbidity and mortality[1]

Daiichi Sankyo Europe GmbH announced the enrolment of the first patient into the PREvention oF thromboembolic events - European Registry in Venous ThromboEmbolism (PREFER in VTE).  PREFER in VTE is the first patient registry to gather comprehensive data on the quality of life and treatment satisfaction of patients with VTE. It will also provide detailed insights into the process of patient management in the acute treatment phase, as well as in the prevention of repeat thromboembolic events. In addition, the PREFER in VTE registry will investigate the economic burden of VTE treatment.  

Discussing the importance of this registry, Dr. Alexander T. Cohen , Honorary Consultant Vascular Medicine, Department of Vascular Surgery, King's College Hospital, London, said, "The enrolment of the first patient in this registry is an exciting milestone. PREFER in VTE is the first registry of its kind that will provide detailed insight into the patient's perspective. Relying on patient interviews and diaries rather than focusing purely on a doctor's assessment of VTE, will give us important patient data outside of a clinical trial setting."

VTE is a leading cause of morbidity and mortality worldwide and the annual number of VTE-related deaths has been estimated at more than 500,000 across the EU.[1] Results of literature reviews have shown that VTE, and its consequences, have considerable economic impacts on healthcare systems.[2]

The PREFER in VTE registry plans to enrol more than 4,000 patients with VTE (deep vein thrombos
'/>"/>

SOURCE Daiichi Sankyo Europe GmbH
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
2. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
3. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
4. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
5. Mylan Launches Generic Lipitor® in Five European Countries
6. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
7. Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
8. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
9. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
10. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  Charleston Laboratories, Inc., an ... second clinical development program with a Phase 1 ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  ... a treatment for migraine headache pain and migraine-induced ... patients with migraine headaches also suffer from nausea ...
(Date:8/3/2015)... and FLORHAM PARK, N.J. ... that once-daily naldemedine met its primary and secondary endpoints ... treatment of opioid-induced constipation (OIC) in adult patients with ... acting mu-opioid receptor antagonist (PAMORA). This is the third ... and key secondary endpoints. Study results showed ...
(Date:8/3/2015)... NESS ZIONA, Israel , August ... BVXV, TASE: BVXV) today announced it received the statistical analysis ... flu vaccine (M-001), administered in the BVX-005 phase II trial ... against future strains which did not exist at the time ... influenza (flu) strain that caused the epidemic in ...
Breaking Medicine Technology:Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
... Company Ltd. announced on August 23 the appointment of Dr. ... Menicon Holdings B.V. Dr. Choo will oversee the company,s Rose ... the company,s growing specialty lens portfolio. For the ... Adventus Technology Inc. and the Brien Holden Vision Institute (BHVI) ...
... the support of Key Opinion Leaders clearly linked to ... attention of KOLs is intensifying. But the changing regulatory ... and maintaining KOL and physician relationships. To ... Practices, LLC has published an updated MSL-focused report that ...
Cached Medicine Technology:Jennifer Choo Joins Menicon as Specialty Lens Clinical Manager 2Pharma Medical Science Liaison Outreach Shifting Away from Traditional Company Sales Regions 2
(Date:8/3/2015)... ... August 03, 2015 , ... Since 1978, the number of black males ... new publication released today by the AAMC (Association of American Medical Colleges). , ... past three decades, the number of black male applicants to medical school dropped to ...
(Date:8/3/2015)... ... ... They know every second counts. And when it comes to stroke, the ... best care in the nation. For the past two months, the stroke team led ... time in the country. During the months of June and July, it took the ...
(Date:8/3/2015)... UK (PRWEB) , ... August 03, 2015 , ... ... R&D services to contract research organisations (CROs) for a slew of benefits, allowing ... global research and operations, boost quality with cost-effective utilisation of resources, get access ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in Los Angeles , ... Most people know that general health emergencies, such as broken arms or a heart ... know where to turn to during a dental emergency. This is important, because dental ...
(Date:8/3/2015)... ... 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and ... Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker ... the Company’s presentation may be accessed via the investor relations section of the Company’s ...
Breaking Medicine News(10 mins):Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... on a baby inside the womb. The baby, Grace, underwent the ... discharged on Friday after the successful completion of the surgery. ... left heart syndrome (HLHS) inside the womb. When she was 30 ... November 7, 2005. ,She was born on January 10 ...
... in a hospital at Brisbane a patient had to be ... attacked and was in serious condition, attention could not be ... Hospital, where emergency services are scarce due to shortage of ... operational from 8am to 6pm every day. ,The ...
... that it intends to fast track its inhaled insulin Exubera ... and Drug Administration // and the European Commission last ... and Nektar Therapeutics. ,It is a relatively harmless ... syringes are needed. "Until today, patients with diabetes who need ...
... successfully reached the Vinson Massif summit, one of Antarctica's ... and was successfully completed on January 19th after eight ... was a strong, healthy athlete who was later diagnosed ... of the disease he lost 80 pounds and his ...
... on the pregnant women. , It ... people are in search for a remedy for it. // ... pregnant women approaching the health care centers for a treatment related to ... to include new information about the management of stress during pregnancy. ...
... reported to be infected with the H5N1 strain, making this ... country, even though the EU rules remain suspended in the ... infection was detected attracts as many as 1 million UK ... is said to be the same that claimed four casualties ...
Cached Medicine News:Health News:Baby Underwent A Heart Surgery Inside The Womb 2Health News:Crohn's Patient Robert Hill’s greatest achievemen 2
Double cuff electronic tourniquet....
... Safety. Convenience. Reliability. Cost. These are ... OR personnel, and administrators. With a special ... most practical elements of todays technology to ... , The A.T.S. 2000 Tourniquet uses ambient ...
... a revolutionary new addition to the Hall® ... PowerPro Battery System is the first and ... on the market. It is a full-function ... the requirements of large bone, small bone, ...
Stryker Instruments, the leader in cordless power, advances orthopaedics with the power, speed, versatility, reliability and performance through its heavy duty powered instruments....
Medicine Products: